TAp63-miRNA-AURKA Axis as a Therapeutic Target for Cutaneous Squamous Cell Carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Invasive cutaneous squamous cell carcinoma (cSCC) has rising incidence and poor prognosis.
• Lack of reliable molecular markers hinders targeted therapy development for cSCC.
• Identifying novel therapeutic targets is crucial for improving patient outcomes.

Purpose of the Study:

• To identify molecular players that suppress the progression and metastasis of cutaneous squamous cell carcinoma.
• To explore the TAp63-miRNA axis as a potential therapeutic strategy for cSCC.

Main Methods:

• Genetic and proteogenomic analyses were performed on mouse and human cSCC models.
• Expression and function of TAp63, miR-30c-2*, and miR-497 were investigated.
• Therapeutic efficacy of miRNA mimics and AURKA inhibition was evaluated in xenograft mouse models.

Main Results:

• TAp63 and its downstream targets, miR-30c-2* and miR-497, were identified as suppressors of cSCC progression and metastasis.
• Mimics of miR-30c-2* or miR-497 significantly suppressed tumor growth in vivo.
• Pharmacologic inhibition of AURKA, a target of miR-497, also reduced tumor growth.

Conclusions:

• The TAp63-miR-30c-2*/miR-497-AURKA axis represents a novel pathway regulating cSCC.
• This axis presents a promising therapeutic target for invasive cutaneous squamous cell carcinoma.
• Targeting this pathway could offer new treatment strategies for patients with poor prognoses.